Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03439462 · ClinicalTrials.gov registry record · Phase 1
Nab-Sirolimus in Combination With FOLFOX & BEV as 1st Line Therapy in Patients With Advanced or Metastatic Colorectal Cancer
A Phase 1 study, sponsored by Aadi Bioscience.
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
NCT03439462 is a Phase 1 study that has completed, run by Aadi Bioscience. The registered enrollment target is 60 participants.
The verdict
NCT03439462, a Phase 1 study, has completed, sponsored by Aadi Bioscience.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
Study Summary
A phase 1/2 multi-center investigation of nab-sirolimus (also known as ABI-009, nab-rapamycin) in combination with mFOLFOX6 and Bevacizumab as first-line therapy in patients with metastatic colorectal cancer
Interventions
- DRUG nab-sirolimus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2018-07-01 |
| Est. Completion | 2022-08-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03439462
The ClinicalTrials.gov registry entry for NCT03439462 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aadi Bioscience, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which nab-sirolimus is the first listed.
NCT03439462 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03439462 about?
NCT03439462 is a clinical study titled "Nab-Sirolimus in Combination With FOLFOX & BEV as 1st Line Therapy in Patients With Advanced or Metastatic Colorectal Cancer". A phase 1/2 multi-center investigation of nab-sirolimus (also known as ABI-009, nab-rapamycin) in combination with mFOLFOX6 and Bevacizumab as first-line therapy in patients with metastatic colorectal cancer
What is the current status of trial NCT03439462?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2018-07-01. Estimated completion is 2022-08-26.
What interventions are being tested in trial NCT03439462?
The interventions under investigation include: nab-sirolimus (DRUG).
Who is sponsoring clinical trial NCT03439462?
This trial is sponsored by Aadi Bioscience, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.